Portal de Periódicos da CAPES

Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study

2015; Elsevier BV; Volume: 18; Issue: 3 Linguagem: Inglês

10.1038/gim.2014.209

1530-0366

Mei W. Baker, Anne Atkins, Suzanne K. Cordovado, Miyono Hendrix, Marie C. Earley, Philip M. Farrell,

Genomics and Rare Diseases

PurposeMany regions have implemented newborn screening (NBS) for cystic fibrosis (CF) using a limited panel of cystic fibrosis transmembrane regulator (CFTR) mutations after immunoreactive trypsinogen (IRT) analysis. We sought to assess the feasibility of further improving the screening using next-generation sequencing (NGS) technology.MethodsAn NGS assay was used to detect 162 CFTR mutations/variants characterized by the CFTR2 project. We used 67 dried blood spots (DBSs) containing 48 distinct CFTR mutations to validate the assay. NGS assay was retrospectively performed on 165 CF screen–positive samples with one CFTR mutation.ResultsThe NGS assay was successfully performed using DNA isolated from DBSs, and it correctly detected all CFTR mutations in the validation. Among 165 screen-positive infants with one CFTR mutation, no additional disease-causing mutation was identified in 151 samples consistent with normal sweat tests. Five infants had a CF-causing mutation that was not included in this panel, and nine with two CF-causing mutations were identified.ConclusionThe NGS assay was 100% concordant with traditional methods. Retrospective analysis results indicate an IRT/NGS screening algorithm would enable high sensitivity, better specificity and positive predictive value (PPV). This study lays the foundation for prospective studies and for introducing NGS in NBS laboratories.